Innova Captab Past Earnings Performance
Past criteria checks 4/6
Innova Captab has been growing earnings at an average annual rate of 25.2%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 17.9% per year. Innova Captab's return on equity is 13.2%, and it has net margins of 10%.
Key information
25.2%
Earnings growth rate
22.8%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 17.9% |
| Return on equity | 13.2% |
| Net Margin | 10.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding Innova Captab Limited's (NSE:INNOVACAP) Performance Completely
Aug 01
Innova Captab (NSE:INNOVACAP) Has A Pretty Healthy Balance Sheet
Jul 19We Think That There Are Issues Underlying Innova Captab's (NSE:INNOVACAP) Earnings
Jun 06What Innova Captab Limited's (NSE:INNOVACAP) P/E Is Not Telling You
May 21Revenue & Expenses Breakdown
How Innova Captab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11,776 | 1,183 | 1,070 | 0 |
| 30 Jun 24 | 11,423 | 1,062 | 1,031 | 0 |
| 31 Mar 24 | 10,813 | 943 | 931 | 0 |
| 31 Dec 23 | 10,596 | 829 | 801 | 0 |
| 30 Sep 23 | 9,991 | 773 | 682 | 0 |
| 30 Jun 23 | 9,379 | 700 | 581 | 0 |
| 31 Mar 23 | 9,264 | 680 | 563 | 0 |
| 31 Dec 22 | 9,018 | 638 | 552 | 0 |
| 31 Mar 22 | 8,005 | 640 | 416 | 0 |
| 31 Mar 21 | 4,107 | 345 | 226 | 0 |
| 31 Mar 20 | 3,733 | 279 | 203 | 0 |
| 31 Mar 19 | 3,558 | 199 | 182 | 0 |
| 31 Mar 18 | 2,362 | 119 | 122 | 0 |
Quality Earnings: INNOVACAP has a high level of non-cash earnings.
Growing Profit Margin: INNOVACAP's current net profit margins (10%) are higher than last year (7.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INNOVACAP's earnings have grown significantly by 25.2% per year over the past 5 years.
Accelerating Growth: INNOVACAP's earnings growth over the past year (53%) exceeds its 5-year average (25.2% per year).
Earnings vs Industry: INNOVACAP earnings growth over the past year (53%) exceeded the Life Sciences industry 37.9%.
Return on Equity
High ROE: INNOVACAP's Return on Equity (13.2%) is considered low.